skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 231  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Material Type:
Article
Add to My Research

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

American journal of nephrology, 2017-12, Vol.46 (6), p.462-472 [Peer Reviewed Journal]

2017 S. Karger AG, Basel ;ISSN: 0250-8095 ;EISSN: 1421-9670 ;DOI: 10.1159/000484633 ;PMID: 29253846

Digital Resources/Online E-Resources

2
Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials
Material Type:
Article
Add to My Research

Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials

BMC medical research methodology, 2024-02, Vol.24 (1), p.39-39 [Peer Reviewed Journal]

2024. The Author(s). ;COPYRIGHT 2024 BioMed Central Ltd. ;2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1471-2288 ;EISSN: 1471-2288 ;DOI: 10.1186/s12874-024-02170-0 ;PMID: 38365599

Full text available

3
Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
Material Type:
Article
Add to My Research

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

Cardiovascular diabetology, 2023-11, Vol.22 (1), p.330-330, Article 330 [Peer Reviewed Journal]

2023. The Author(s). ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-023-02027-8 ;PMID: 38017482

Full text available

4
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Material Type:
Article
Add to My Research

A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors

Cell metabolism, 2021-04, Vol.33 (4), p.732-739 [Peer Reviewed Journal]

2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;ISSN: 1550-4131 ;EISSN: 1932-7420 ;DOI: 10.1016/j.cmet.2021.02.016 ;PMID: 33691091

Full text available

5
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Material Type:
Article
Add to My Research

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications

Circulation (New York, N.Y.), 2016-09, Vol.134 (10), p.752-772 [Peer Reviewed Journal]

2016 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;2016 American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.116.021887 ;PMID: 27470878

Full text available

6
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Material Type:
Article
Add to My Research

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors

Kidney international, 2018-07, Vol.94 (1), p.26-39 [Peer Reviewed Journal]

2018 International Society of Nephrology ;Copyright © 2018 International Society of Nephrology. Published by Elsevier Inc. All rights reserved. ;ISSN: 0085-2538 ;EISSN: 1523-1755 ;DOI: 10.1016/j.kint.2017.12.027 ;PMID: 29735306

Full text available

7
Dapagliflozin in Patients with Chronic Kidney Disease
Material Type:
Article
Add to My Research

Dapagliflozin in Patients with Chronic Kidney Disease

The New England journal of medicine, 2020-10, Vol.383 (15), p.1436-1446 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2024816 ;PMID: 32970396

Full text available

8
High-Density Lipoprotein Particles and Their Relationship to Posttransplantation Diabetes Mellitus in Renal Transplant Recipients
Material Type:
Article
Add to My Research

High-Density Lipoprotein Particles and Their Relationship to Posttransplantation Diabetes Mellitus in Renal Transplant Recipients

Biomolecules (Basel, Switzerland), 2020-03, Vol.10 (3), p.481 [Peer Reviewed Journal]

COPYRIGHT 2020 MDPI AG ;2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2218-273X ;EISSN: 2218-273X ;DOI: 10.3390/biom10030481 ;PMID: 32245262

Full text available

9
Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
Material Type:
Article
Add to My Research

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment

Journal of the American Society of Nephrology, 2017-04, Vol.28 (4), p.1023-1039 [Peer Reviewed Journal]

Copyright © 2017 by the American Society of Nephrology. ;Copyright © 2017 by the American Society of Nephrology 2017 ;ISSN: 1046-6673 ;EISSN: 1533-3450 ;DOI: 10.1681/asn.2016060666 ;PMID: 28143897

Full text available

10
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial
Material Type:
Article
Add to My Research

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Circulation (New York, N.Y.), 2020-02, Vol.141 (5), p.407-410 [Peer Reviewed Journal]

2020 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.119.044359 ;PMID: 31707795

Full text available

11
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
Material Type:
Article
Add to My Research

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

Journal of the American Society of Nephrology, 2021-09, Vol.32 (9), p.2352-2361 [Peer Reviewed Journal]

Copyright © 2021 by the American Society of Nephrology. ;Copyright © 2021 by the American Society of Nephrology 2021 ;ISSN: 1046-6673 ;EISSN: 1533-3450 ;DOI: 10.1681/asn.2021020167 ;PMID: 34272327

Full text available

12
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Material Type:
Article
Add to My Research

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

Journal of the American Society of Nephrology, 2020-05, Vol.31 (5), p.1128-1139 [Peer Reviewed Journal]

Copyright © 2020 by the American Society of Nephrology. ;Copyright © 2020 by the American Society of Nephrology 2020 ;ISSN: 1046-6673 ;EISSN: 1533-3450 ;DOI: 10.1681/asn.2019111168 ;PMID: 32354987

Full text available

13
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function
Material Type:
Article
Add to My Research

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function

Clinical journal of the American Society of Nephrology, 2017-05, Vol.12 (5), p.751-759 [Peer Reviewed Journal]

Copyright © 2017 by the American Society of Nephrology. ;Copyright © 2017 by the American Society of Nephrology 2017 ;ISSN: 1555-9041 ;EISSN: 1555-905X ;DOI: 10.2215/cjn.10180916 ;PMID: 28302903

Full text available

14
Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation
Material Type:
Article
Add to My Research

Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation

Journal of the American Society of Nephrology, 2019-09, Vol.30 (9), p.1756-1769 [Peer Reviewed Journal]

Copyright © 2019 by the American Society of Nephrology. ;Copyright © 2019 by the American Society of Nephrology 2019 ;ISSN: 1046-6673 ;EISSN: 1533-3450 ;DOI: 10.1681/asn.2019010009 ;PMID: 31292198

Full text available

15
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
Material Type:
Article
Add to My Research

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

Diabetes care, 2021-08, Vol.44 (8), p.1894-1897 [Peer Reviewed Journal]

Copyright American Diabetes Association Aug 1, 2021 ;2021 by the American Diabetes Association 2021 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc21-0300 ;PMID: 34183431

Full text available

16
HDL Particle Subspecies and Their Association With Incident Type 2 Diabetes: The PREVEND Study
Material Type:
Article
Add to My Research

HDL Particle Subspecies and Their Association With Incident Type 2 Diabetes: The PREVEND Study

The journal of clinical endocrinology and metabolism, 2021-06, Vol.106 (6), p.1761-1772 [Peer Reviewed Journal]

The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. 2021 ;The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. ;COPYRIGHT 2021 Oxford University Press ;ISSN: 0021-972X ;EISSN: 1945-7197 ;DOI: 10.1210/clinem/dgab075 ;PMID: 33567068

Full text available

17
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
Material Type:
Article
Add to My Research

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Diabetes care, 2021-08, Vol.44 (8), p.1805-1815 [Peer Reviewed Journal]

Copyright American Diabetes Association Aug 1, 2021 ;2021 by the American Diabetes Association 2021 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc21-0076 ;PMID: 34233928

Full text available

18
Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium
Material Type:
Article
Add to My Research

Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium

American journal of kidney diseases, 2019-02, Vol.73 (2), p.206 [Peer Reviewed Journal]

ISSN: 1523-6838 ;EISSN: 1523-6838 ;DOI: 10.1053/j.ajkd.2018.08.013

Digital Resources/Online E-Resources

19
Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D
Material Type:
Article
Add to My Research

Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D

Journal of the American Society of Nephrology, 2022-05, Vol.33 (5), p.996-1010 [Peer Reviewed Journal]

Copyright © 2022 by the American Society of Nephrology. ;Copyright © 2022 by the American Society of Nephrology 2022 ;ISSN: 1046-6673 ;EISSN: 1533-3450 ;DOI: 10.1681/asn.2021060735 ;PMID: 35314457

Full text available

20
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Material Type:
Article
Add to My Research

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL

Diabetes care, 2019-02, Vol.42 (2), p.318-326 [Peer Reviewed Journal]

2018 by the American Diabetes Association. ;Copyright American Diabetes Association Feb 1, 2019 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc18-1871 ;PMID: 30523029

Full text available

Results 1 - 20 of 231  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (226)

Refine My Results

Creation Date 

From To
  1. Before 2016  (2)
  2. 2016 To 2017  (28)
  3. 2018 To 2019  (35)
  4. 2020 To 2022  (114)
  5. After 2022  (53)
  6. More options open sub menu

Searching Remote Databases, Please Wait